Clinical Trial Update: Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Lantus (insulin glargine) with NPH insulin in people with Type 1 diabetes experiencing Dawn phenomenon; study completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dawn Phenomenon
• Type 1 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)
• NPH insulin (insulin isophane)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Type 1 Diabetes, Dawn Phenomenon | Phase 3 | Status: COMPLETED | Results posted: 2014-10-21